Pharnext (FR:ALPHA) has released an update.
Pharnext SCA, a biopharmaceutical company specializing in neurodegenerative therapies, has requested judicial liquidation due to its inability to finance operations beyond July 15, 2024. The Paris Commercial Court will review the request on August 22nd. Shareholders are warned of potential capital losses and significant dilution from previous financing operations.
For further insights into FR:ALPHA stock, check out TipRanks’ Stock Analysis page.
